IL-6 and hsCRP are promising biomarkers for advancing precision medicine in heart failure by improving individual risk assessment and guiding anti-inflammatory interventions.
IL-6 and hsCRP have emerged as important markers of residual inflammatory risk in HF. Elevated levels of these biomarkers are associated with increased risk of incident HF and adverse outcomes in established disease. While hsCRP is as a downstream marker of inflammation with no causal involvement, Mendelian randomization studies support a causal role of IL-6 signaling in the development of HF and coronary artery disease. Recent and ongoing clinical trials support the concept of targeting inflammatory pathways as a therapeutic strategy in selected HF populations. Inflammatory biomarkers, particularly IL-6 and hsCRP, are promising tools for advancing precision medicine in HF by improving individual risk assessment and guiding anti-inflammatory interventions. Further large-scale studies are needed to validate the integration of inflammatory biomarkers into clinical algorithms for HF and explore their potential role in future guideline recommendations and personalized prevention strategies.
Kurt et al. (Thu,) studied this question.